id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-295270-6ptaxg74	Titanji, Boghuma K	Response to Correspondence: Baricitinib – Impact on COVID-19 Coagulopathy? Jorgensen et. al.	2020-08-14		.txt	text/plain	501	54	63	authors: Titanji, Boghuma K; Farley, Monica M; Schinazi, Raymond F; Marconi, Vincent C Baricitinib through its immunomodulatory effects as highlighted by Jorgensen et.al may in fact be beneficial in terms of reducing coagulopathy in patients with COVID-19, which is thought to be primarily mediated by hyper-inflammation and endothelial damage. All of the cohort studies of baricitinib for COVID-19 treatment led to significant decline in inflammatory M a n u s c r i p t markers for patients who received the drug 2,3,8 . Regarding baricitinib, ACTT2 should provide clarity on the VTE issue in the near future and its role in the treatment of COVID-19 in moderate to severe patients. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Use of Baricitinib in patients with moderate and severe COVID-19 Vincent Marconi and Raymond F Schinazi are partially funded by -Emory University Center for AIDS Research (AI050409).	./cache/cord-295270-6ptaxg74.txt	./txt/cord-295270-6ptaxg74.txt